Zanamivir: an alternative translation.
This paper offers an alternative view to that given elsewhere regarding the value of zanamivir as an agent for treating patients who develop influenza symptoms. The position taken here has developed as a result of an analysis of the data that was undertaken by the journal Drug and Therapeutics Bulletin.
Collier
J
J
St George's Hospital Medical School, Department of Pharmacology and Clinical Pharmacology, Cranmer Terrace, London SW17 0RE, UK. jcollier@sghms.ac.uk
D000998:Antiviral Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006077:Government Agencies; D006146:Guanidines; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy; D017410:Practice Guidelines as Topic / Q000592:standards*; D011714:Pyrans; D012794:Sialic Acids / Q000627:therapeutic use*; D006113:United Kingdom; D053243:Zanamivir
D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053243:Zanamivir